Alnylam Pharmaceuticals Inc at Nasdaq Virtual Investor Conference Transcript
Good morning. My name is David Lebowitz. I'm 1 of the biotechnology analysts at Morgan Stanley. Before I get going, let me just read you the important disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please please reach out to your Morgan Stanley sales representative. I'd like to welcome you all once again to the 43rd NASDAQ Investor Conference, and I'm happy to have with me, from Alnylam Pharmaceuticals, CFO, Jeff Poulton. Jeff, thank you very much for being here. I guess before we get started, could you just give us a topline overview of Alnylam Pharmaceuticals, it's really a unique company, it's a platform-based company. You've had 3 drugs approved within the last 2 years, which is really quite remarkable. You have a unique technology called RNA interference could you tell us about the history, where it's come from and where it's going?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
